Genome & Company
B-8F Silicon Park, 35 Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13486
Consent to collection and use of personal information (Required)
Genome & Company (the ”Company”) regards the protection of personal information of our users very important, and complies with relevant laws, including the Personal Information Protection Act and the Act on Expansion of Dissemination and Promotion of Utilization of Information System. The Company hereby informs the purpose and method of using the personal information provided by our users through the Company’s website, and what measures are taken to protect the personal information. If the Company revises any of this Private Policy, it will be notified through the notices on the Company’s website (or individually notified).
The Company collects the following personal information to operate its Contact Service via the Company’s website (whereby the users can make general inquires, inquiry for business development, IR inquiry, media inquiry, etc.).
- Essential Information: name, e-mail address, phone number, organization, content of inquiry
- Collection method: The Company collects the personal information through the inquiries submitted via the Contact Bulletin Board on the Company’s website.
You have the right to refuse the ‘collection of essential information’ as well as the ‘collection of optional information’. If you refuse the collection of essential information, however, you may be restricted for using the Contact Service.
The following information may be automatically generated and collected in the process of using the website.
- IP Address, cookie, date and time of visit, records of service use
The Company uses the collected personal information for the following purposes.
- Personal verification, personal identification, delivery of inquiries and notification of results (answers and responses), etc. related to the use of Contact Service
In principle, the collected personal information is destroyed without any delay after achieving the purpose of collecting and using personal information. However, the Company may keep users’ information for a certain period of time as required by relevant laws.
- Retained information: personal information submitted with the inquiry, content of the inquiry, and ensuing responses
- Relevant Law: Act on the Consumer Protection in Electronic Commerce, etc.
- Retention Period: three years (records related to resolution of consumer complaints or disputes)
In principle, the information is destroyed without any delay after achieving the purpose of collecting and using personal information. The procedure and method of destruction are as follows.
The personal information submitted is transferred to a separate database (in case of paper, separate cabinet) after achieving the purpose and kept for a certain period of time according to the internal policy and other relevant laws, before it is destroyed. The personal information transferred to separate database shall not be used any other purposes other than for keeping in accordance with laws.
2) Destruction Method
Personal information saved in the form of electronic file shall be deleted by using technical method that cannot reproduce the records. Personal information printed in the paper shall be destroyed by shredding with a shredder or incinerating it.
In case users request the correction of any errors in personal information, we shall not use or provide the personal information until such correction is made. In addition, in case incorrect personal information is already provided to a third party, we will notify the third party the result of correction without delay.
The Company processes and destroys personal information at the request of users or their legal representatives in accordance with Section ‘3. Processing of Personal Information and Retention Period’ and Section ‘4. Destruction of Personal Information’, and such information shall not be opened or used for any other purposes.
The Company designates data protection officer and manager for managing personal information as follows to protect users’ personal information related to inquiries.
Data Protection Officer
Name: Seo Yeong-jin
Department: Business management
Data Protection Manager
Name: Seol Su-gi
Department: PR team
Position: Team Lead
You can submit to the personnel above any inquiries related to your personal information submitted to the Company while using our web service. The Company will quickly provide sufficient responses to your inquiries.
Please contact the below agencies if you need report or counseling for any infringement of personal data privacy.
- Personal Information Infringement Report Center (privacy.kisa.or.kr / 118 without area code)
- Personal Information Dispute Mediation Committee (kopico.go.kr / 1833-6972)
- Cyber Investigation Department, Supreme Prosecutor’s Office (www.spo.go.kr / 1301 without area code)
- Cyber Bureau of the National Police Agency (http://cyberbureau.police.go.kr / 182 without area code)
Genome & Company establishes affiliate List Bio in the U.S. and constructs a large-scale microbiome manufacturing facility in Fishers
n Genome & Company established its affiliate List Biotherapeutics, Inc. in October for the microbiome CDMO business
n Scheduled to build a microbiome manufacturing facility of 59,504㎡ in Fishers, Indiana and will receive generous incentives such as a free site for the production facility a 50% reduction in property tax from Fishers in the U.S.
[2021.11.19] Genome & Company (314130, CEO: Jisoo Pae∙Hansoo Park), a leading global immuno-oncology company establishes an affiliate List Biotherapeutics, Inc. (herein after List Bio, CEO Yongwan Jo) in the U.S. and builds a large-scale microbiome manufacturing facility in Fishers, Indiana, U.S.
In October, Genome & Company established its U.S. affiliate List Bio to focus on the microbiome CDMO business and plans to manufacturing organization (CMO) facility on 59,504㎡ in the Fishers Life Science & Innovation Park in Fishers and create 210 new jobs. Regarding this project, List Bio will be receiving a free site for the production facility and a 50% reduction in property tax from Fishers in the U.S. for 15 years after the completion of the facility. In addition, The Indiana Economic Development Corporation (IEDC) and local companies promised additional support such as facility usage fee reduction and tax deductions.
City of Fishers, located in Indiana USA, has a population of around 100,000 as of 2019 and is one of the cities in which the technology and life science industry are developing rapidly. Fishers Life Science & Innovation Park is being evaluated as having high-quality pharmaceutical and bio infrastructure, talent, and companies in related fields. Recently, life science companies such as Stevenato Group and INCOG Pharma made investments worth 230 billion won or about 200 million dollars in Fishers.
In the future, Genome & Company will operate its affiliates Scioto Biosciences, List Labs and List Bio separately, attract new investments for each company through separate operations, and maximize synergy by utilizing the advantages of each company.
Yongwan Jo CEO of List Bio said, “Through the new plant, we plan to start the development and production of microbiome therapeutics at the clinical and commercial level in earnest.” adding, “Through List Labs’ 40 years of experience and know-how, We will make a leap forward as a ‘first mover’.”
Jisoo Pae CEO of Genome & Company said, "It is meaningful to be able to take over the management rights of microbiome CDMO List Labs in September, establish a new plant first time in Fishers and will make great synergy together." “We are going to make all-out efforts to develop into FIPCO (Fully Integrated Pharmaceutical Company) which allows for both R&D and production.”
# # #
[Photo 1] Genome & Company CI
[Photo 2] List Bio CEO Yongwan Jo Fishers Mayor Scott Fadness
▶Introduction of Genome & Company
Genome & Company is a global pharmaceutical and bio company that focuses on 1) microbiome therapeutics and consumer products and 2) new drug target-based anticancer drugs based on ample clinical data and Multi-Omics technology since its establishment in 2015. In particular, we are focusing on developing next-generation innovative new drugs in the fields of the microbiome and new target anti-cancer drugs to meet the medical demand of cancer patients which was unmet due to a lack of existing cytotoxic anticancer drugs and targeted anti-cancer drugs. In the future, Genome & Company will not only accelerate R&D of innovative treatments with high demand using microbiome and new targets but also expand the capabilities related to production and commercialization to grow into a Fully Integrated Pharmaceutical Company.
# # #